Second malignancies in patients with Ewing Sarcoma Family of Tumors: A population-based study

Sultan, Iyad; Rihani, Rawad; Hazin, Ribhi; Rodríguez‐Galindo, Carlos

doi:10.3109/02841860903253538

Cited by 32 publications

(45 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to more intensive treatment protocols used, patients with EWS are at higher cumulative risk of developing secondary malignancies compared to most other cancers of children and young adults [1–4]. Rarely, EWS itself is diagnosed as a secondary malignancy [5–7].…”

Section: Introductionmentioning

confidence: 99%

Clinical features and outcomes in patients with secondary Ewing sarcoma

Applebaum¹,

Goldsby²,

Neuhaus³

et al. 2012

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Ewing sarcoma (EWS) is rarely diagnosed as a second malignancy. We sought to describe a cohort of patients with secondary EWS and investigate if patient characteristics and survival differ between patients with secondary and primary EWS. Procedure Patients with EWS or peripheral primitive neuroectodermal tumor (PNET) reported to the SEER database from 1973 to 2008 were evaluated based on primary or secondary tumor sequence. Overall survival was estimated by Kaplan-Meier methods and evaluated using the log-rank test. Competing risk analysis was used to describe risk of death due to malignancy rather than other causes. Results 58 cases of secondary EWS were reported, accounting for 2.1% of all EWS cases. The median latency from primary malignancy to secondary EWS was 64 months (range 1–282 months). 12.1% of patients with secondary EWS received radiation to the site of secondary tumor during therapy for their primary malignancy. Patients with secondary EWS were more likely to have axial tumors (77.4% vs. 62.5%; p = 0.03) and smaller tumors (75.0% vs. 48.2% < 8 cm; p = 0.001). Five-year overall survival from diagnosis was inferior for patients with secondary compared to primary EWS (34.3% vs. 52.2%; p = 0.002). However, patients with secondary tumors were less likely than those with primary EWS to die from their malignancy (hazard ratio 0.44; 95% CI 0.23–0.85). Conclusions Secondary EWS accounts for a minority of cases of EWS. Tumor size and site and patient survival differ among patients with primary and secondary EWS.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical features and outcomes in patients with secondary Ewing sarcoma

Applebaum¹,

Goldsby²,

Neuhaus³

et al. 2012

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The ES-specific survival is about 75% overall [ (Schrager et al, 2011) and this study]. EW is under active research to identify biological, pathological, and socio-economic barriers to improvement of the clinical outcome (Friedman et al, 2010;Sultan et al, 2010;Worch et al, 2010;Jawad et al, 2011;Schrager et al, 2011;Applebaum et al, 2012). Along this line, this study used the receiver operating characteristic (ROC) curve to analyze Surveillance, Epidemiology and End Results (SEER) EW outcome data.…”

Section: Introductionmentioning

confidence: 99%

Optimization of Predictors of Ewing Sarcoma Cause-specific Survival: A Population Study

Cheung¹

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The risk of SMN was higher in patients diagnosed with ES before the age of 20 years. Two of these patients developed third malignancies [29]. …”

Section: Incidence Of Second Malignancies After Ewing's Sarcomamentioning

confidence: 99%

Ewing's Sarcoma and Second Malignancies

Schiffman

Wright

2011

Sarcoma

View full text Add to dashboard Cite

Ewing's sarcoma (ES) is a rare tumor that is most common in children and young adults. Late effects of ES therapy include second cancers, a tragic outcome for survivors of such a young age. This paper will explore the frequencies and types of malignancies that occur after ES. Additionally, it will review how second malignancies have changed with the shift in treatment from high-dose radiation to chemotherapy regimens including alkylators and epipodophyllotoxins. The risk of additional cancers in ES survivors will also be compared to survivors of other childhood cancers. Finally, the possible genetic contribution to ES and second malignancies will be discussed.

show abstract

Second malignancies in patients with Ewing Sarcoma Family of Tumors: A population-based study

Cited by 32 publications

References 25 publications

Clinical features and outcomes in patients with secondary Ewing sarcoma

Clinical features and outcomes in patients with secondary Ewing sarcoma

Optimization of Predictors of Ewing Sarcoma Cause-specific Survival: A Population Study

Ewing's Sarcoma and Second Malignancies

Contact Info

Product

Resources

About